M. Marquis

发表

Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 cells.

Yves Bousquet, J. Gillard, P. Beaulieu, 2004, Journal of medicinal chemistry.

Molecular dynamics simulations and structure-based rational design lead to allosteric HCV NS5B polymerase thumb pocket 2 inhibitor with picomolar cellular replicon potency.

O. Hucke, P. Bonneau, C. Brochu, 2014, Journal of medicinal chemistry.

A Disulfide-bridged Mutant of Natriuretic Peptide Receptor-A Displays Constitutive Activity

M. Marquis, J. Labrecque, A. De Léan, 1999, The Journal of Biological Chemistry.

In Vitro Resistance Profile of the Hepatitis C Virus NS3 Protease Inhibitor BI 201335

G. Kukolj, M. Massariol, P. White, 2011, Antimicrobial Agents and Chemotherapy.

Studyin a Phase 1b Multiple-Rising-Dose NS3 Protease Inhibitor Faldaprevir (BI Genotype 1-Infected Patients Receiving the Viral Resistance in Hepatitis C Virus

G. Kukolj, R. Bethell, M. Marquis, 2014 .

Viral Resistance in Hepatitis C Virus Genotype 1-Infected Patients Receiving the NS3 Protease Inhibitor Faldaprevir (BI 201335) in a Phase 1b Multiple-Rising-Dose Study

G. Kukolj, R. Bethell, M. Marquis, 2013, Antimicrobial Agents and Chemotherapy.

Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.

M. Massariol, P. White, M. Marquis, 2010, Biochemical and biophysical research communications.

Discovery of BI 207524, an indole diamide NS5B thumb pocket 1 inhibitor with improved potency for the potential treatment of chronic hepatitis C virus infection.

J. Duan, M. Garneau, P. Anderson, 2014, Journal of medicinal chemistry.

An NS3 Serine Protease Inhibitor Abrogates Replication of Subgenomic Hepatitis C Virus RNA*

D. Lamarre, A. Pause, G. Kukolj, 2003, Journal of Biological Chemistry.

Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.

C. Trautwein, V. de Lédinghen, G. Gerken, 2012, Journal of hepatology.

Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment

X. Forns, P. Beaulieu, G. Kukolj, 2009, Antiviral therapy.

758 CHARACTERIZATION OF RESISTANT MUTANTS SELECTED IN VITRO BY THE HCV NS3/4A PROTEASE INHIBITOR BI 201335

G. Kukolj, M. Massariol, P. White, 2010 .

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir

G. Kukolj, C. Sarrazin, D. Nelson, 2016, PloS one.

Binding Site Characterization and Resistance to a Class of Non-nucleoside Inhibitors of the Hepatitis C Virus NS5B Polymerase*

Louise Thauvette, Graham A. McGibbon, P. Beaulieu, 2005, Journal of Biological Chemistry.

Chronic Hepatitis C Polymerase Inhibitor, in Patients with an Investigational Hepatitis C Virus RNA Administration of Deleobuvir (BI 207127), Pharmacokinetics of Five-Day Oral Antiviral Effect, Safety, and

G. Kukolj, A. Lohse, M. Marquis, 2014 .

Antiviral Effect, Safety, and Pharmacokinetics of Five-Day Oral Administration of Deleobuvir (BI 207127), an Investigational Hepatitis C Virus RNA Polymerase Inhibitor, in Patients with Chronic Hepatitis C

G. Kukolj, A. Lohse, M. Marquis, 2013, Antimicrobial Agents and Chemotherapy.

Baseline Hepatitis C Virus (HCV) NS3 Polymorphisms and Their Impact on Treatment Response in Clinical Studies of the HCV NS3 Protease Inhibitor Faldaprevir

G. Kukolj, M. Massariol, M. Marquis, 2013, Antimicrobial Agents and Chemotherapy.

Characterization of the phosphorylation state of natriuretic peptide receptor-C

M. Marquis, A. De Léan, N. McNicoll, 2004, Molecular and Cellular Biochemistry.

Comparative binding study of rat natriuretic peptide receptor-A

M. Marquis, M. Bouvier, A. De Léan, 1999, Molecular and Cellular Biochemistry.

1185 CHARACTERIZATION OF HCV NS3 VARIANTS THAT EMERGED DURING VIROLOGIC BREAKTHROUGH AND RELAPSE FROM BI 201335 PHASE II SILEN-C2 STUDY IN PEGIFN/RBV TREATMENT-EXPERIENCED PATIENTS

T. Asselah, G. Kukolj, R. Bethell, 2012 .